CBB1007

inhibits lysine-specific demethylase 1

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Residual Neoplasm 11/15/2015 - "Profiling MEST and RXRγ for curcumin and CBB1007, respectively, indicated an inability of curcumin and CBB1007 in restricting residual tumor regenerative capabilities. "
2.	Ovarian Neoplasms (Ovarian Cancer) 10/29/2013 - "Effects on cell viability (MTS/PMS assay) of six LSD1 inhibitors (pargyline, TCP, RN-1, S2101, CAS 927019-63-4, and CBB1007) were also evaluated in a panel of ovarian cancer cell lines (SKOV3, OVCAR3, A2780 and cisplatin-resistant A2780cis). "

1.	Pargyline (Pargyline Hydrochloride)
2.	Curcumin
3.	Cisplatin (Platino)